UK AMR Diagnostic Collaborative Launch
July 5th 2018, London
Hosted by NHS England on behalf of the UK AMR Diagnostic Collaborative
July 5th 2018 will see the formal launch of the Collaborative at the Wellcome Collection, London, to coincide with the 70th Birthday of the NHS. This launch will set out the ambitions and plans for the UK ADC in 2018/19.
The UK ADC was formed to specifically consider and respond to the issues related to diagnostics as outlined in the O’Neill review. A global ambition with regard to diagnostics is quoted in the final report as:
“High-income countries should make it mandatory that by 2020 the prescription of antibiotics will need to be informed by data and testing technology wherever it is available.”
The UK ADC membership comprises of colleagues across the health system and includes devolved nations. It’s focus is to consider how best the UK can respond to this ambition and define a plan that articulates key actions to take this work forward.
Agenda, venue and ticket information below...
The launch will be held at the Wellcome Collection, London
Address: 183 Euston Road, London NW1 2BE
How to get there
We have five Sheffield cycle stands near the front entrance to Wellcome Collection on Euston Road and three stands to the side of the building on Gordon Street. Please be aware that bicycles are left at the owner's risk. There are Santander docking stations in front of Wellcome Collection on Euston Road and behind the building on Gower Place. Further docking stations can be found ne
By car/coach We have limited car parking space for blue badge holders only. More info. Wellcome Collection cannot accommodate coaches, so you will need to make your own parking arrangements if you are planning on bringing a group by coach. Please refer to TfL guidance for coaches. Please see our group visits page if you are planning to bring a group of eight or more people to visit Well.
UK AMR Diagnostic Collaborative Launch Event 5th July 2018
08:30-09.25 Delegate registration & Breakfast
09:25-09:30 Chair's Introduction
Professor Sue Hill, Chief Scientific Officer for England
09:30-09:45 Keynote speech - Outlining the challenge of AMR and sharing the role diagnostics can play
Professor Dame Sally Davies, Chief Medical Officer for England
09:45-10:00 Event open - Introducing the UKADC
Fiona Carragher, Deputy Chief Scientific Officer for England
10:00-10:30 AMR Diagnostic Stewardship Ambitions
Professor Neil Woodford, Deputy Director NIS Laboratories, Public Health England
· Impact of the blood culture pathway
Michael Weinbren, Director Infection Prevention and Control, Consultant Microbiologist, UHCW
· To Dip or Not to Dip - Improving the management of Urinary Tract Infections
Elizabeth Beech, English national project leads for Healthcare Associated Infections and Antimicrobial Resistance
· CRP – A primary care view
Andrew McGinty,General Practitioner & Clinical Director, NHS Sheffield CCG
10:30-11:00 Refreshment break & networking
11:00-11:25 Superbug strategy - with Q&A session
Lord O’Neill of Gatley
11:25-11:45 Journey of an Innovator
Russ Watkins, Director of Business Innovation and Improvement, Newcastle Foundation Trust
11:45-12:05 The role of Genomics
Dr Noel Craine, Research Scientist, Public Health Wales
12:05-12:20 AMR Diagnostics: Barriers & Economics
Phil Packer, Innovation Lead: AMR and Vaccines, Ageing Society, Health & Nutrition,
12:20-12:30 Sepsis – a 360 approach
Mat Inada-Kim, Clinical Lead for Sepsis/Deterioration for Wessex Patient Safety Collaborative & Kordo Saeed, Consultant Clinical Microbiologist, Hampshire Hospitals NHS Foundation Trust
12:30-12:50 Q&A with audience
12:50-13:00 Closing remarks
Fiona Carragher, Deputy Chief Scientific Officer, NHS England
Fiona is the Deputy Chief Scientific Officer for England, supporting the head of profession for the 50,000 healthcare science workforce in the NHS and associated bodies.
A significant part of Fiona's role involves working across government, with system partners and other external stakeholders to inform policy, influence legislation, deliver strategic change and introduce new and innovative ways of working.
Fiona is a clinical biochemist, with a strong background in both public health and treatment & care, having been regional director of the Newborn blood spot screening programme. Fiona worked in multi-professional teams for two decades with a focus on providing high quality, innovative laboratory services.
Matt is an Acute Medicine consultant on a 50 bedded acute medical unit, Matt is the Clinical Lead for Sepsis/Deterioration for Wessex Patient Safety Collaborative and National Clinical Advisor on Sepsis and Deterioration. Matt was a Harkness Fellow at the Commonwealth Fund and travelled and studied other countries health systems; he came away with the strong belief that the NHS is the best and fairest healthcare system in the world ‘every day I see incredible examples of what NHS staff do for patients and the difference they make, and this strengthens my resolve to help make the system as a whole- more effective, more efficient and as safe as possible’.
Matt remembers the first three patients that died under his care, they all succumbed to sepsis which led to his career long interest in improving the awareness, recognition and treatment of patients with this condition. Matt believes that if we are to improve our outcomes in sepsis then all cause deterioration pathways need to be created to ensure that sepsis is considered in all sick patients and that it is noted, that not all deteriorations are due to sepsis.
Matt’s partner is a nurse and they have 3 boys (who all keep him well grounded), Matt enjoys cooking and playing acoustic guitar.
Lord Jim O'Neill
Lord O’Neill will become the Chair of Chatham House In July.
Jim is the Vice Chair of the Northern Powerhouse Partnership. Lord O’Neill is also Chairing the International Advisory Board for the Productivity Insights Network+ Programme, co-ordinated by Sheffield University. He is a member of the Shelter Social Housing Commission.
Since leaving from Government in September 2015, having been Commercial Secretary to the Treasury, Jim moved to the Crossbenches of the House of Lords.
Jim led an independent Review into Antimicrobial Resistance ( AMR) for David Cameron from late 2014 to September 2016, and remains focused on this challenge. He has recently published a book, “ Superbugs, An Arms Race Against Bacteria” with two of his Review team colleagues, and was also awarded a Fellowship from the Society for Applied Microbiology for his AMR work.
In 2013/ 2014, Jim chaired the Cities Growth Commission in the UK, which formed the impetus for the government’s policy on devolution as well as the concept of the Northern Powerhouse.
Jim worked for Goldman Sachs from 1995 until April 2013, spending most of his time there as Chief Economist.
Before 1995, Jim had worked for Swiss Bank Corporation, Marine Midland Bank and Bank of America, starting in the City in 1982.
Jim is the creator of the acronym “BRIC” and has conducted much research about these and other emerging economies. He has published various books on the topic, and in early 2014 made a documentary series for the BBC entitled MINT:The Next Economic Giants. He writes frequently on these and many other international economic and financial topics for leading international media.
He is one of the founding trustees of the UK educational charity, SHINE.
Jim has served on many educational foundation boards, as well as having served on the boards of a number of international organisations and think tanks.
Jim served as a non-executive director of Manchester United before it returned to private ownership in 2005.
Jim earned BA and MA degrees in economics from Sheffield University in 1978 and a PhD from the University of Surrey in 1982. He has honorary degrees from the Institute of Education, University of London, for his educational philanthropy, from City University for his services to banking and finance, and from Sheffield University in recognition of his contribution to international economics. Jim is an Honorary Fellow of the Faculty of Public Health , a Fellow at the Society for Applied Microbiology,and a Fellow of the Academy of Social Sciences.
Elizabeth Beech currently works as one of three English national project leads for Healthcare Associated Infections and Antimicrobial Resistance within the Patient Safety Team at NHS Improvement - supporting the implementation of the UK Antimicrobial Resistance Strategy, in particular within commissioning and primary care. Elizabeth also works as a pharmacist in NHS Bath and North East Somerset CCG, participates in AMR related research, and is an active member of the Q community. Elizabeth set up the #ToDipOrNotToDip community of interest to improve the management of UTI in older people in social care, and is delighted this is expanding to include all types of care settings – contact Elizabeth.email@example.com for an invitation to join the community on Slack.
Professor Dame Sally C Davies FRS FMedSci
Dame Sally is the Chief Medical Officer for England (CMO) and Chief Medical Advisor to the UK Government. She is an independent advisor to the UK Government on medical and public health matters.
Dame Sally founded the National Institute for Health Research and is a Non-Executive Director of Genomics England Ltd. She was a member of the WHO Executive Board and the Strategic and Technical Advisory Group on Antimicrobial Resistance (AMR). Dame Sally received her DBE in 2009, and is an elected Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, UK, and a member of the National Academy of Medicine, USA. Most recently, she has been appointed a co-convener of the UN Inter-Agency Co-ordination Group on AMR, set up in response to the UNGA 2016 declaration.
Dame Sally first became captivated by AMR when she published her 2011 CMO annual report on infectious diseases, highlighting the increasing threat of AMR and calling for global action to address key areas including stewardship, monitoring and surveillance, and antibiotic development. Since then, Dame Sally has led the way advocating globally for an effective response to AMR and continues to raise public awareness through a variety of mediums, including the publication of The Drugs Don’t Work book, a TED talk, and through the media.
Professor Neil Woodford is a Consultant Clinical Scientist. In April 2018, he became Deputy Director NIS Laboratories within Public Health England’s National Infection Service. He is a Visiting Professor at Imperial College London and is co-Director of the WHO Collaborating Centre for Reference and Research on Antimicrobial Resistance and Healthcare Associated Infections. Neil has worked on antimicrobial resistance for over three decades and has co-authored over 400 publications and edited three books on this subject. A Fellow of the Royal College of Pathologists, he was the scientific adviser to Lord Jim O’Neill’s independent Review on AMR and sits on many national and international advisory committees and working groups.
Dr Noel Craine
Noel works as a research scientist for Public Health Wales and is based in North Wales. His current research interests focus on the epidemiology of infectious disease supporting the work of Public Health Wales on health care associated infections and AMR and also on national work addressing the challenge of hepatitis C virus. Noel has a particular interest in translating epidemiological research into tangible health benefits for the population of Wales.
Dr Phil Packer
Dr Phil Packer, Innovation Lead Antimicrobial, Resistance & Vaccines
I joined Innovate UK in September 2017.
Prior to this I held various research and research management positions within the public sector. Most recently I managed a research programme for Dstl that included the development of medical countermeasures against biological and chemical agents, diagnostics, trauma care, regenerative medicine and hearing loss. My first job at Dstl was the management of the UK plague vaccine programme. Previous to this I worked at CAMR where I completed a Ph.D and post-doctoral research in cancer and biofilms before moving into ECACC as Quality Manager.
Russell Watkins, Assistant Director – Business Innovation & Improvement, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Russ is the Assistant Director – Business Innovation & Improvement for Newcastle Hospitals. Russ leads on innovation for the Trust and has developed a strategy and process for developing new ideas for staff and well as leading on bidding for all procurements with the Trust. Russ has a key role working with colleagues in Newcastle University and is involved in most of the research and innovation platforms / awards held within the City; including the MRC Pathology Node and the NIHR Medtech and In vitro diagnostic Co-operatives (MIC). This work has led to the formation of Diagnostics North East which primary aim to assist companies to gather evidence for adoption of their diagnostic product.
Mike became a consultant microbiologist in 1990. Whilst working at University Hospitals Coventry and Warwickshire he first became interested in optimising the blood culture pathway. Together with Ian Sturgess their involvement was key in updating SMI B 37 on blood culture processing.
In 2013 Mike moved to the Chesterfield Royal Hospital where a multi-disciplinary team was set up to optimise the blood culture pathway, winning a regional NHS innovation award for their work. The work was unique in utilising blood science staff not only to load the blood culture analyser 24 hours / day but also to begin processing positive blood cultures outside of routine microbiology working hours. Mike has been involved in a number of national and regional surveys of blood culture practice.
Professor Dame Sue Hill
Professor Dame Sue Hill
She is a respiratory scientist by background with an international academic and clinical research reputation. Professor Hill has a broad portfolio of policy responsibilities across the health and care system and provides professional leadership and expert clinical advice across the whole health and care system.
For the past decade she has led a variety of major system and workforce transformation initiatives for the Government to improve patient outcomes and service effectiveness in the NHS and beyond.
In particular, Sue is the Senior Responsible Officer for Antimicrobial Diagnostics, a key part of the Government’s Antimicrobial Resistance Strategy.
She is also SRO for Genomics, having led the establishment and ongoing direction of the NHS Genomic Medicine Centres and the NHS contribution to the 100,000 Genomes Project; SRO for the Hearing programme and SRO for the NHS Home Oxygen Service.
Dr Andrew McGinty
Dr Andrew McGinty, Clinical Director for Active Ageing, Cancer, End of Life Care and Long-term Conditions, Caldicott Guardian for NHS Sheffield Clinical Commissioning Group
I spend the majority of my working week as a General Practitioner in the the practice I joined in 1999. The rest of my working week is spent as a Clinical Director for NHS Sheffield CCG. I have been involved in commissioning since 2008 and have been in my role as Clinical Director since 2015. My commissioning role now focuses on people with long term conditions, frailer and older people and prescribing issues amongst other things and this has led me to have a keen interest in Antimicrobial Stewardship as the people who are the focus of my work often get infections that may or may not require antimicrobial therapy.
Having studied at the Universities of St Andrews and Manchester I gained a Bachelor of Medical Science along the way to my medical degree in 1992. I spent a couple of years in Anaesthesia, often treating sepsis first hand in Intensive Care Units, before turning my attention to General Practice. I became a partner in my practice in 2000 and a member of the RCGP the same year.
My practice is on the outskirts of Sheffield in a mainly elderly former mining community with a significant burden of multi-morbidity. In my day to day practice I am often faced with trying to help the patient with me understand if they require an antibiotic or not, and I'm glad the other half of me is involved in trying to make the answer to that question appear sooner with more accuracy and be financially sustainable to both my practice and the NHS.